daunorubicin hydrochloride injection solution
hikma canada limited - daunorubicin (daunorubicin hydrochloride) - solution - 20mg - daunorubicin (daunorubicin hydrochloride) 20mg
vyxeos daunorubicin (as hydrochloride) 44 mg and cytarabine 100 mg powder for injection vial
jazz pharmaceuticals anz pty ltd - daunorubicin, quantity: 44 mg; cytarabine, quantity: 100 mg - injection, powder for - excipient ingredients: cholesterol; sucrose; distearoylphosphatidylglycerol; trolamine; copper gluconate; distearoylphosphatidylcholine - vyxeos is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-aml) or aml with myelodysplasia-related changes (aml-mrc)
daunorubicin 20mg powder for solution for infusion vials
zentiva pharma uk ltd - daunorubicin hydrochloride - powder for solution for infusion - 20mg
daunorubicin injection 20 mg/10 ml (1)
pfizer (perth) pty ltd - daunorubicin hydrochloride, quantity: 2.14 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - - acute lymphocytic (lymphoblastic) leukaemia. daunorubicin is usually reserved for use in cases shown to be resistant to other drugs. however, combined treatment with daunorubicin, vincristine and a steroid has been used in the early stages of the disease. - acute myeloblastic leukaemia. daunorubicin has been used in all stages, alone or in combination with other cytotoxic agents e.g., cytarabine. - disseminated solid tumours. daunorubicin has been investigated for use in these tumours and found to be effective in some cases of disseminated neuroblastoma and rhabdomyosarcoma.
daunoxome 2 mg/ml concentrate for soln for inf
galen limited - daunorubicin citrate - concentrate for soln for inf - 2 mg/ml
daunoxome 50mg/25ml concentrate for solution for infusion vials
galen ltd - daunorubicin citrate liposomal - solution for infusion - 2mg/1ml
daunorubicin 20mg powder for i.v. injection
cherubino limited delf building, sliema road, gzira, gzr 1637, malta - daunorubicin - powder for injection - daunorubicin 20 mg - antineoplastic agents
daunorubicin
daunorubicin -
pfizer (australia) daunorubicin (as hydrochloride) 20mg/10ml injection vial
pfizer australia pty ltd - daunorubicin, quantity: 20 mg - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - indications as at 22 november 2004 : daunorubicin injection is indicated for the treatment of the following: acute lymphocytic (lymphoblastic) leukaemia: daunorubicin is usually reserved for use in cases shown to be resistant to other drugs. however, combined treatment with daunorubicin, vincristine and a steroid has been used in the early stages of this disease. acute myeloblastic leukaemia: daunorubicin has been used in all stages, alone or in combination with other cytotoxic agents (e.g. cytarabine). disseminated solid tumours: daunorubicin has been investigated for use in these tumours and found to be effective in some cases of disseminated neuroblastoma and rhabdomyosarcoma.
daunorubicin injection 20 mg in 10 ml (2)
pfizer (perth) pty ltd - daunorubicin hydrochloride, quantity: 2.14 mg/ml - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - daunorubicin is an anthracycline, antineoplastic agent used as a standard component of various regimes for the treatment of leukemia. disseminated tumors - daunorubicin has been investigated for use in these tumors and has found to be effective in some cases of disseminated neuroblastoma and rhabdomyosarcoma.